Sitagliptin

Sitagliptin is a DPP‑4 inhibitor with modest HbA1c reduction and cardiovascular neutrality; it has no demonstrated heart failure outcome benefit. DPP-4 inhibitors may in fact exacerbate heart failure symptoms through oedema worsening. This is not the best drug for Mr. Green.

Please go back and re-consider. 

  • Opción 3 [undo]
  • Λήψη Ιστορικού σχετικά με την COVID-19 [undo]
  • Total Body CT scan [undo]
  • You suggest that we work together with the doctors at the hospital. [undo]
  • Start a therapy [undo]
  • Increases her coffee intake [undo]
  • Opțiunea 1: Pentru siguranța noastră și a colegilor noștri în timpul și după practica de laborator [undo]
  • Πολυμεράση Taq [undo]
  • Ask the patient to walk or change position (risk of falling). [undo]
  • Amlodipine (calcium channel blocker) [undo]
  • Urina pacientului conține glucoză. [undo]
  • Calcium: Increased; Potassium: Decreased; Sodium: Decreased [undo]
  • new node [undo]
  • Spironolactone (aldosterone antagonist) [undo]
  • Răspunsul 2 [undo]
  • Sitagliptin [undo]

Map: Michael Green_GEMD_2 (1116)
Node: 21125
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway